Sofosbuvir and daclatasvir combination therapy for current hepatitis C virus genotype 4 achieves SVR: a case report of HCV genotype 4 from the Amazon
Rev. Soc. Bras. Med. Trop; 50 (6), 2017
Publication year: 2017
Abstract Hepatitis C is a worldwide endemic disease. However, hepatitis C virus genotype 4 (HCV GT-4) has rarely been reported in Brazil. HCV GT-4 demonstrates high sustained virological response (SVR). Here, we report the case of a 62-year-old HCV GT-4 positive woman complaining of a headache, nausea, and arthralgia. The patient was treated according to the protocol for genotype 4 (12 weeks administration of 400mg sofosbuvir and 60mg daclatasvir daily) and achieved SVR. Although this is not an Amazonas autochthonous case, the presence of genotype 4 is rarely reported in the region.
Antivirales/administración & dosificación, Quimioterapia Combinada, Genotipo, Hepacivirus/genética, Hepatitis C Crónica/tratamiento farmacológico, Hepatitis C Crónica/genética, Hepatitis C Crónica/virología, Imidazoles/administración & dosificación, Persona de Mediana Edad, Sofosbuvir/administración & dosificación, Respuesta Virológica Sostenida, Resultado del Tratamiento